A year after receiving the PacBio RS single-molecule sequencer in their labs, early-access customers from two research institutions have taken their instruments through their paces and are starting to analyze "real" samples.
Complete Genomics shipped fewer genomes than forecast in the fourth quarter of 2011, and as a result was downgraded by investment firm Oppenheimer from an 'Outperform' to a 'Perform' rating.